Parvovirus B19-Induced Membranoproliferative Glomerulonephritis in an Immunocompetent Adult Patient: A Case Report

免疫功能正常的成年患者发生细小病毒B19诱发的膜增生性肾小球肾炎:病例报告

阅读:1

Abstract

A 41-year-old woman without significant medical history was admitted for edema and a 10 kg weight gain. Two months earlier, she had experienced a flu-like syndrome treated with amoxicillin. At admission, she presented with severe hypertension and stage 1 acute kidney injury. Work-up revealed nephrotic syndrome, microscopic hematuria, and transient biological hemolysis. Type II cryoglobulinemia was identified, along with complement consumption. Autoimmune and viral serologies were negative. Renal biopsy revealed a full-house membranoproliferative glomerulonephritis (MPGN). She was initially treated as having type II cryoglobulinemic MPGN with rituximab, corticosteroids, and nephroprotection. Subsequently, an acute coexisting parvovirus B19 infection was confirmed by seropositivity for IgG and IgM and high viremia. This was associated with an inflammatory articular flare. Rituximab was stopped and replaced by intravenous immunoglobulin (IVIg), leading to clinical and renal remission and viral clearance over a 10-month period. Although rare, parvovirus B19 is a known cause of lupus-like MPGN, even in immunocompetent adults. Failure to recognize primary parvovirus B19 infection exposes patients to diagnostic delay and unwarranted treatment. Timely IVIg therapy avoids persistent disease and prevents treatment escalation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。